Risk factors
Taysha Gene Therapies (TSHA) risk factors
Item 1A of every Taysha Gene Therapies, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors104 risks13 new11 dropped25 reworded
Taysha advanced its lead gene therapy TSHA-102 into pivotal trials, losing emerging growth company status and increasing compliance burdens.
Filed Mar 19, 2026 - FY2024 10-K risk factors102 risks
Taysha Gene Therapies is heavily reliant on the clinical and regulatory success of its lead candidate, TSHA-102 for Rett syndrome. The company faces significant financial constraints, having accumulated a $602.3 million deficit as of December 31, 2024. Manufacturing complexities and heavy reliance on third-party contract manufacturers for gene therapies threaten clinical timelines.
Filed Feb 26, 2025